Last checked at 13 Sep 2022 08:13
CORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu
(Correcting that Bristol-Myers gained US FDA approval, not Sareum.)
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Sareum Share News (SAR)
SAR Share
Price
SAR Share
News
SAR Share
Chat
SAR Share
Trades67
SAR
Live RNS
SAR Share
Charts
SAR Level 2
Console
SAR Live
Share Price
SAR Broker
Ratings
SAR Directors
Deals
SAR Financial
Diary
SAR
Fundamentals
SAR Short
Positions
SAR
Media
Sareum Information
Share Price Information for Sareum (SAR)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
25.25
Bid:
25.00
Ask:
25.50
Change:
-2.00 (-7.34%)
Spread:
0.50 (2.00%)
Open:
26.75
High:
26.75
Low:
25.25
Prev. Close:
27.25
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Sareum confident of at least one deal in 2012
Mon, 27th Feb 2012 14:57
Penny stock Sareum, which develops drugs to combat cancer, saw its losses widen in the second half of 2011, in line with the board's expectations. The firm's losses after tax deepened from £0.26m to £0.33m, which the firm said reflects an increase in research and development. Pre-tax losses totalled £0.36m versus £0.28m in the second half of 2010.The company ended the half year with net assets of £0.55m, most of which was accounted for by £0.53m in cash. The cash pile stood at £0.62m at the end of 2010, so it is diminishing but not at a precipitous rate.Despite moving further into the red, the company is sticking by its present structure and funding model as it believes this is making the most effective use of available funds and resources to drive programmes forward rather than being used to build infrastructure. Revenues from early deals will be used to progress the in-house programmes and reduce the need to generate investment from shareholders, the company said.The board reckons that, despite the current economic environment, the appetite for licensing deals in the pharmaceuticals arena remains strong and the company expects at least one licensing deal to be completed in 2012. Operating losses rose from £283m to £361m as the firm developed its drug discovery programmes. The firm's biggest success during the period was the selection of the pre-clinical candidate compound from the Chk1 inhibitor programme which is run as a joint collaboration with The Institute of Cancer Research and Cancer Research Technology. This compound has been submitted to further testing to generate pre-clinical safety data. The share price fell 12.31% to 1.43p by 15:09.NR
More News
12 Sep 2022 12:27
Sareum receives US US Food & Drug Administration approval for Sotyktu
(Alliance News) - Sareum Holdings PLC on Monday said the US Food & Drug Administration has approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor.
Read more4 Jul 2022 11:23
IN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737
Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum.
Read more10 Jun 2022 11:19
Midatech Chair Rolf Stahel retires; Stephen Parker named as successor
(Alliance News) - Midatech Pharma PLC on Friday said that Chair Rolf Stahel plans to leave the board on June 20, and it named Stephen Parker as his successor.
Read more13 Apr 2022 21:59
TRADING UPDATES: Sureserve gets new CFO; Sareum notes GSK buys Sierra
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more13 Apr 2022 19:46
TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more11 Apr 2022 20:51
TRADING UPDATES: Pod Point wins BMW deal; Lamprell seals contract
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more16 Mar 2022 14:21
Sareum progresses Covid-19 and autoimmune treatment candidate
(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human trials on Wednesday.
Read more21 Feb 2022 18:13
TRADING UPDATES: Bank of Cyprus swings profit; Sareum loss widens
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more21 Feb 2022 15:55
UK shareholder meetings calendar - next 7 days
| Tuesday 22 February | |
| Aberdeen Diversified Income & Growth Trust PLC | AGM |
| Image Scan Holdings PLC | AGM |
| Montanaro European Smaller Cos Trust PLC | GM share issue |
| Wednesday 23 February | |
| Blencowe Resources PLC | AGM |
| Gooch & Housego PLC | AGM |
| Income & Growth VCT PLC | GM re share subscription |
| Mobeus Income & Growth 2 VCT PLC | GM re share subscription |
| Mobeus Income & Growth 4 VCT PLC | GM re share subscription |
| Mobeus Income & Growth VCT PLC | GM re share subscription |
| RWS Holdings PLC | AGM |
| Tharisa PLC | AGM |
| Titon Holdings PLC | AGM |
| Thursday 24 February | |
| Bankers Investment Trust PLC | AGM |
| IntegraFin Holdings PLC | AGM |
| Victorian Plumbing Group PLC | AGM |
| Friday 25 February | |
| Caledonian Trust PLC | AGM |
| GRIT Investment Trust PLC | AGM |
| Henderson Diversified Income Trust PLC | GM re investment policy |
| On the Beach Group PLC | AGM |
| Ruffer Investment Co Ltd | EGM re authority to issue shares |
| Monday 28 February | |
| Alternative Liquidity Fund Ltd | EGM |
| Ramsdens Holdings PLC | AGM |
| Sareum Holdings PLC | EGM re share consolidation |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
4 Feb 2022 14:37
IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation
IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation
Read more17 Dec 2021 19:28
IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes
IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes
Read more9 Dec 2021 14:43
UK shareholder meetings calendar - next 7 days
UK shareholder meetings calendar - next 7 days
Read more23 Nov 2021 16:21
DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares
DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares
Read more25 Oct 2021 08:48
Sareum full-year loss widens on research & development costs
Sareum full-year loss widens on research & development costs
Read more